建立一种新的多药耐药的诱导方法

目的建立裸鼠原位肝癌耐药模型。方法培养肝癌细胞系HepG2,建立裸鼠的皮下肿瘤,形成“供瘤鼠”。开腹直视下将瘤块种植于裸鼠的肝包膜下建立原位肝癌模型,通过表阿霉素间歇腹腔化疗,建立裸鼠原位肝癌耐药模型。用体检、B超、CT、剖腹探查监测肝内瘤块生长情况。用逆转录聚和酶链反应(RT-PCR)和免疫组织化学方法检测肿瘤耐药基因mdrl-mRNA和p-gp蛋白的表达。结果(1)模型建立无手术死亡(0/25),种植成瘤率为88%(22/25),补种3例全部成功,耐药诱导成功率为80%(16/20);(2)诱导组mdrl-mRNA和P-gp蛋白的表达均明显高于对照组,分别约是对照组的23倍和13倍。结论成功地建立了与临床肝癌相似的裸鼠原位肝癌耐药模型,为进一步研究肝癌多药耐药基因的诊断和逆转提供了良好的动物平台。

Establishment of a mdr1 Multidrug Resistant Model of Orthotopic Transplantation of Liver Carcinoma on Nude Mice

Objective: To develop a new method of inducing mdr1 multidrug resistance by establishing a nude mice model of orthotopic transplantation of liver carcinoma by sporadic abdominal chemotherapy at intervals. Methods: Hepatocellular carcinoma HepG2 cell was cultured and injected subcutaneously to form the tumor-supplying mice. The tumor bits from the tumor-supplying mice were implanted under the envelope of the mice liver and induced by abdominal chemotherapy with Pharmorubicin. Physical examination, ultrasonography. spiral CT and operative inspection were used to examine tumor progression. RT-PCR and immunohistochemistry were adopted to detect the expression of mdr1-mRNA and its encoded protein P-gp protein (P-gp). Results: There was no operative dead, the rate of implanting tumor successfully was 88% (22/25), the rate of implanting secondly successfully was 100% (3/3). and the rate of inducing successfully was 80% (16/20). The expression of mdrl-mRNA and the P-gp in the inducing group was 23 folds and 13 folds in the control group respectively. Conclusion: We have established an in vivo model of rndr using nude mice transplanted with orthotopic liver neoplasm coupled to chemotherapy.